Alisertib, an aurora kinase inhibitor, promotes apoptosis and autophagy in human osteosarcoma U-2 OS and MG-63 cells by activating mitochondrial pathways and inhibiting the p38 MAPK/PI3K/Akt/mTOR signaling pathway [53]. Here, MTOR is linked to osteosarcoma.